Inactief instrument

Andere talen BioPlus Acquisition Corp.

Aandelen

BIOS

KYG112171171

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index	10-10-23
BioPlus Acquisition, Avertix Medical Terminate Business Combination Deal	04-10-23
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate	04-10-23
Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.	04-10-23
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring	16-08-23
BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors	17-07-23
Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando	13-06-23
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	08-06-23
BioPlus Acquisition Corp. announced that it has received $1.5 million in funding	02-06-23
BIOPLUS ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	30-05-23
BioPlus Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03-05-23
Avertix Medical, Inc. entered into a definitive merger agreement to acquire BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others for approximately $170 million in a reverse merger transaction.	03-05-23
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	31-03-23
BioPlus Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31-03-23
BioPlus Acquisition Corp. Auditor Raises 'Going Concern' Doubt	31-03-23
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	03-11-22
BioPlus Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03-11-22
BIOPLUS ACQUISITION CORP. : Other Events (form 8-K)	11-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioPlus Acquisition Corp.

Aandelen

BIOS

KYG112171171

Andere talen

Filters